Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study

J. Harrington, Kevin; Burtness, Barbara; Greil, Richard; Soulières, Denis; Tahara, Makoto; de Castro, Gilberto; Psyrri, Amanda; Braña, Irene; Basté, Neus; Neupane, Prakash; Bratland, Åse; Fuereder, Thorsten; Hughes, Brett; Mesı́a, Ricard; Ngamphaiboon, Nuttapong; Rordorf, Tamara; Zamaniah Wan Ishak, Wan; Lin, Jianxin; Gümüşçü, Burak; F. Swaby, Ramona; Rischin, Danny

doi:10.1200/jco.21.02508

Public

Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study

Published in Journal of Clinical Oncology • Oct 11, 2022

Authors:

Kevin J. Harrington

Barbara Burtness

Richard Greil

Abstract

PURPOSE: Pembrolizumab and pembrolizumab-chemotherapy demonstrated efficacy in recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048. Post hoc analysis of long-term efficacy and progression-free survival on next-line therapy (PFS2) is presented. METHODS: Patients were randomly as...

Subject

Pembrolizumab

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!